Journal Article
. 2022 Mar; 12:809709.
doi: 10.3389/fonc.2022.809709.

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Qi Li 1 Mengran Cao 2 Guosheng Yuan 1 Xiao Cheng 3 Mengya Zang 1 Ming Chen 4 Xiaoyun Hu 1 Jing Huang 3 Rong Li 1 Yabing Guo 1 Jian Ruan 4 Jinzhang Chen 1 
Affiliations
  • PMID: 35280760
  •     61 References

Abstract

Background: Combining an antiangiogenic agent with an anti-PD-1 agent is a promising strategy for unresectable hepatocellular carcinoma (HCC).

Aims: To explore the effectiveness and tolerability of lenvatinib plus camrelizumab vs. lenvatinib monotherapy as a first-line treatment for unresectable HCC.

Methods: This multicenter, retrospective cohort study included patients with unresectable HCC treated with oral lenvatinib 8 mg daily and intravenous camrelizumab 200 mg every 3 weeks (L+C group) or lenvatinib 12 mg or 8 mg daily (L group) in four Chinese centers between September 2018 and February 2020. Tumor response was evaluated according to RECIST 1.1 and mRECIST. The outcomes included objective response rate (ORR), overall survival (OS), 1-year OS rate, progression-free survival (PFS), and safety.

Results: By March 31, 2021, 92 patients were finally included, with 48 and 44 in the L+C and L groups, respectively. ORR was significantly higher in the L+C group than in the L group (RECIST 1.1: 37.5% vs. 13.6%, P=0.009; mRECIST: 41.7% vs. 20.5%, P=0.029). Median OS and 95% confidence interval (CI) was 13.9 (13.3-18.3) months in the L group and not reached in the L+C group (P=0.015). The 1-year survival rate was 79.2% and 56.8% in the L+C and L groups, respectively. Median PFS was 10.3 (6.6-14.0) months and 7.5 (5.7-9.3) months in the L+C and L groups, respectively (P=0.0098). Combined therapy vs. monotherapy was independently associated with a prolonged OS (hazard ratio=0.380, 95% CI=: 0.196-0.739, P=0.004) and a prolonged PFS (hazard ratio=0.454, 95%CI=0.282-0.731, P=0.001). The safety profile was comparable between the two groups. The most common adverse event in the L+C and L groups was loss of appetite (41.7% vs. 40.9%, P=0.941). Three patients in the L+C group and two in the L group terminated treatment owing to adverse events.

Conclusion: First-line lenvatinib plus camrelizumab showed better effectiveness than lenvatinib alone in patients with unresectable HCC.

Keywords: camrelizumab; hepatocellular carcinoma; lenvatinib; objective response; survival; unresectable.

The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors.
Matthew H Taylor, Emmett V Schmidt, +4 authors, Drew Rasco.
Future Oncol, 2020 Dec 11; 17(6). PMID: 33300372
Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis.
Katsuaki Ogushi, Makoto Chuma, +26 authors, Shin Maeda.
Clin Exp Gastroenterol, 2020 Oct 17; 13. PMID: 33061517    Free PMC article.
Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients.
Bruno Carvalho, Rafaela Gonçalves Lopes, +6 authors, Rui Vaz.
J Neurooncol, 2020 Jan 25; 147(1). PMID: 31974803
Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial.
Akihito Kawazoe, Shota Fukuoka, +10 authors, Kohei Shitara.
Lancet Oncol, 2020 Jun 27; 21(8). PMID: 32589866
Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis.
Cheng Huang, Xiao-Dong Zhu, +8 authors, Hui-Chuan Sun.
Biomark Res, 2021 Mar 22; 9(1). PMID: 33743822    Free PMC article.
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Richard S Finn, Masafumi Ikeda, +17 authors, Josep M Llovet.
J Clin Oncol, 2020 Jul 28; 38(26). PMID: 32716739    Free PMC article.
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Masaaki Kondo, Manabu Morimoto, +14 authors, Katsuaki Tanaka.
BMC Cancer, 2019 Oct 17; 19(1). PMID: 31615466    Free PMC article.
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.
Masatoshi Kudo.
Cancers (Basel), 2020 May 01; 12(5). PMID: 32349374    Free PMC article.
Review.
Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting.
Takuya Sho, Goki Suda, +23 authors, Naoya Sakamoto.
JGH Open, 2020 Feb 15; 4(1). PMID: 32055698    Free PMC article.
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib.
Alessandro Granito, Sara Marinelli, +3 authors, Luigi Bolondi.
Therap Adv Gastroenterol, 2016 Mar 02; 9(2). PMID: 26929785    Free PMC article.
Review.
Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
Huijuan Cheng, Guodong Sun, +6 authors, Yumin Li.
Am J Cancer Res, 2019 Sep 10; 9(8). PMID: 31497341    Free PMC article.
Review.
Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.
Fabio Piscaglia, Sadahisa Ogasawara.
Liver Cancer, 2018 Apr 18; 7(1). PMID: 29662837    Free PMC article.
Review.
Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.
Leila Khoja, Gireesh Kumaran, +8 authors, Jurjees Hasan.
J Clin Gastroenterol, 2013 Oct 25; 48(5). PMID: 24153157
The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma.
Allen Jacob, Jaret Shook, Thomas Hutson.
Expert Rev Anticancer Ther, 2021 Jan 05; 21(4). PMID: 33393393
Review.
Experience with regorafenib in the treatment of hepatocellular carcinoma.
Alessandro Granito, Antonella Forgione, +6 authors, Francesco Tovoli.
Therap Adv Gastroenterol, 2021 Jun 10; 14. PMID: 34104211    Free PMC article.
Review.
Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review.
Dun-Chang Mo, Peng-Hui Luo, +2 authors, Jian-Feng Huang.
Int Immunopharmacol, 2020 Dec 19; 91. PMID: 33338862
Systematic Review.
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Robert Motzer, Boris Alekseev, +36 authors, CLEAR Trial Investigators.
N Engl J Med, 2021 Feb 23; 384(14). PMID: 33616314
[Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)].
Department of Medical Administration, National Health and Health Commission of the People's Republic of China.
Zhonghua Gan Zang Bing Za Zhi, 2020 Mar 14; 28(2). PMID: 32164061
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng, Yoon-Koo Kang, +18 authors, Zhongzhen Guan.
Lancet Oncol, 2008 Dec 20; 10(1). PMID: 19095497
Highly Cited.
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.
Viktor Grünwald, Thomas Powles, +11 authors, Robert J Motzer.
Future Oncol, 2019 Jan 29; 15(9). PMID: 30689402
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
A Vogel, A Cervantes, +13 authors, ESMO Guidelines Committee.
Ann Oncol, 2018 Oct 05; 29(Suppl 4). PMID: 30285213
Highly Cited.
Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.
Haijing Deng, Anna Kan, +12 authors, Ming Zhao.
Liver Cancer, 2020 Jul 11; 9(3). PMID: 32647635    Free PMC article.
Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system.
Chia-Yang Hsu, Yun-Hsuan Lee, +7 authors, Teh-Ia Huo.
Hepatology, 2012 Jul 19; 57(1). PMID: 22806819
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases.
Jorge A Marrero, Laura M Kulik, +5 authors, Julie K Heimbach.
Hepatology, 2018 Apr 07; 68(2). PMID: 29624699
Highly Cited.
Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.
Xiao-Dong Zhu, Cheng Huang, +12 authors, Hui-Chuan Sun.
Liver Cancer, 2021 Aug 21; 10(4). PMID: 34414120    Free PMC article.
2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights.
Di-Yang Xie, Zheng-Gang Ren, +2 authors, Qiang Gao.
Hepatobiliary Surg Nutr, 2020 Aug 25; 9(4). PMID: 32832496    Free PMC article.
Review.
Survival Analysis of Advanced HCC Treated with Radioembolization: Comparing Impact of Clinical Performance Status Versus Vascular Invasion/Metastases.
Rehan Ali, Ahmed Gabr, +7 authors, Robert J Lewandowski.
Cardiovasc Intervent Radiol, 2017 Sep 08; 41(2). PMID: 28879621
Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date.
Alison L Raybould, Hanna Sanoff.
J Hepatocell Carcinoma, 2020 Sep 29; 7. PMID: 32984090    Free PMC article.
Review.
Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
Fuqun Wei, Qizhen Huang, +2 authors, Yongyi Zeng.
Cancer Manag Res, 2021 Jun 04; 13. PMID: 34079375    Free PMC article.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Vicky Makker, Matthew H Taylor, +16 authors, Antonio Casado Herraez.
J Clin Oncol, 2020 Mar 14; 38(26). PMID: 32167863    Free PMC article.
Hepatocellular Carcinoma.
Augusto Villanueva.
N Engl J Med, 2019 Apr 11; 380(15). PMID: 30970190
Highly Cited. Review.
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
Vicky Makker, Nicoletta Colombo, +22 authors, Study 309–KEYNOTE-775 Investigators.
N Engl J Med, 2022 Jan 20; 386(5). PMID: 35045221
Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Al B Benson, Michael I D'Angelica, +33 authors, Susan D Darlow.
J Natl Compr Canc Netw, 2021 May 25; 19(5). PMID: 34030131
Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria.
Takuya Sho, Goki Suda, +22 authors, Naoya Sakamoto.
Hepatol Res, 2020 Jun 21; 50(8). PMID: 32562334
Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis.
Kang Wang, Wei Xing Guo, +10 authors, Shu Qun Cheng.
Medicine (Baltimore), 2016 Mar 18; 95(11). PMID: 26986115    Free PMC article.
Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma.
Jie Mei, Yu-Hao Tang, +4 authors, Rong-Ping Guo.
Front Oncol, 2021 Mar 16; 11. PMID: 33718175    Free PMC article.
Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal.
CA Cancer J Clin, 2021 Jan 13; 71(1). PMID: 33433946
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.
Laura Torrens, Carla Montironi, +17 authors, Josep M Llovet.
Hepatology, 2021 Jun 23; 74(5). PMID: 34157147
Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis.
Hiroyuki Ogawa, Kosuke Kaji, +8 authors, Hitoshi Yoshiji.
J Cell Mol Med, 2021 Feb 21; 25(8). PMID: 33609067    Free PMC article.
Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
Takeshi Terashima, Tatsuya Yamashita, +11 authors, Shuichi Kaneko.
Hepatol Res, 2020 Apr 21; 50(7). PMID: 32307874
A global view of hepatocellular carcinoma: trends, risk, prevention and management.
Ju Dong Yang, Pierre Hainaut, +3 authors, Lewis R Roberts.
Nat Rev Gastroenterol Hepatol, 2019 Aug 24; 16(10). PMID: 31439937    Free PMC article.
Highly Cited. Review.
Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma.
Robin Park, Fariha Eshrat, +2 authors, Anwaar Saeed.
Vaccines (Basel), 2020 Aug 14; 8(3). PMID: 32784389    Free PMC article.
Review.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Chung-Han Lee, Amishi Yogesh Shah, +25 authors, Robert J Motzer.
Lancet Oncol, 2021 Jun 19; 22(7). PMID: 34143969    Free PMC article.
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Richard S Finn, Shukui Qin, +19 authors, IMbrave150 Investigators.
N Engl J Med, 2020 May 14; 382(20). PMID: 32402160
Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: a case report.
Ke Wang, Haoyang Wang, +3 authors, Ying Zhang.
Ann Palliat Med, 2021 Feb 07; 10(1). PMID: 33545802
Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer.
Mengmeng Lu, Xiaokang Zhang, +11 authors, Qing Zhang.
Pharmacol Res, 2021 Aug 20; 174. PMID: 34411731
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.
Jaime Feliu, Antonieta Salud, +12 authors, Joan Maurel.
PLoS One, 2015 Jan 21; 10(1). PMID: 25602286    Free PMC article.
The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
Yun Wang, Man Jiang, +6 authors, Xiaochun Zhang.
Biomed Pharmacother, 2020 Oct 18; 132. PMID: 33068935
Review.
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Vicky Makker, Drew Rasco, +13 authors, Matthew Taylor.
Lancet Oncol, 2019 Mar 30; 20(5). PMID: 30922731
Highly Cited.
Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Song Chen, Zhiqiang Wu, +9 authors, Wenbo Guo.
J Cancer Res Clin Oncol, 2021 Aug 29;. PMID: 34453221
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis.
Shaily Arora, Sanjeeve Balasubramaniam, +9 authors, Julia A Beaver.
Clin Cancer Res, 2020 Apr 17; 26(19). PMID: 32295834
Review.
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Kuimin Mei, Shukui Qin, +3 authors, Jianjun Zou.
J Immunother Cancer, 2021 Mar 21; 9(3). PMID: 33741732    Free PMC article.
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Zhenggang Ren, Jianming Xu, +38 authors, ORIENT-32 study group.
Lancet Oncol, 2021 Jun 19; 22(7). PMID: 34143971
Lenvatinib and pembrolizumab in advanced gastric cancer.
Stefano Cascinu.
Lancet Oncol, 2020 Jun 27; 21(8). PMID: 32589865
Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis.
Jaekyung Cheon, Hong Jae Chon, +7 authors, Baek-Yeol Ryoo.
Liver Cancer, 2020 Oct 22; 9(5). PMID: 33083284    Free PMC article.
Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma.
Sara Bedrose, Kevin Charles Miller, +12 authors, Mouhammed Amir Habra.
J Immunother Cancer, 2020 Aug 02; 8(2). PMID: 32737143    Free PMC article.
Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review.
Wei-Xun Chen, Gan-Xun Li, +3 authors, Ze-Yang Ding.
Medicine (Baltimore), 2019 Nov 09; 98(45). PMID: 31702638    Free PMC article.
Review.
Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.
Jianzhen Lin, Xu Yang, +20 authors, Haitao Zhao.
Hepatobiliary Surg Nutr, 2020 Aug 25; 9(4). PMID: 32832493    Free PMC article.
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
Jeffrey J Wallin, Johanna C Bendell, +19 authors, David F McDermott.
Nat Commun, 2016 Aug 31; 7. PMID: 27571927    Free PMC article.
Highly Cited.
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
Matthew H Taylor, Chung-Han Lee, +6 authors, Robert J Motzer.
J Clin Oncol, 2020 Jan 22; 38(11). PMID: 31961766    Free PMC article.